98 related articles for article (PubMed ID: 9566711)
41. Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95.
Seidemann K; Zimmermann M; Book M; Meyer U; Burkhardt B; Welte K; Reiter A; Stanulla M
J Clin Oncol; 2005 Nov; 23(33):8414-21. PubMed ID: 16293872
[TBL] [Abstract][Full Text] [Related]
42. Association between restriction fragment length polymorphism of the L-myc gene and lung metastasis in human breast cancer.
Champeme MH; Bieche I; Latil A; Hacene K; Lidereau R
Int J Cancer; 1992 Jan; 50(1):6-9. PubMed ID: 1345822
[TBL] [Abstract][Full Text] [Related]
43. Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas.
Sarmanová J; Benesová K; Gut I; Nedelcheva-Kristensen V; Tynková L; Soucek P
Hum Mol Genet; 2001 Jun; 10(12):1265-73. PubMed ID: 11406608
[TBL] [Abstract][Full Text] [Related]
44. Allelic variation of the c-raf-1 proto-oncogene in human lymphoma and leukemia.
Trench GC; Southall M; Smith P; Kidson C
Oncogene; 1989 Apr; 4(4):507-10. PubMed ID: 2566145
[TBL] [Abstract][Full Text] [Related]
45. Analysis of L-myc gene polymorphism in patients with renal failure outcome to renal transplant.
Yigit B; Bozkurt N; Yaylim I; Titiz I; Isbir T
Transplant Proc; 2006 Jun; 38(5):1267-9. PubMed ID: 16797278
[TBL] [Abstract][Full Text] [Related]
46. Polymorphisms in folate-metabolizing genes and risk of non-Hodgkin's lymphoma.
Weiner AS; Beresina OV; Voronina EN; Voropaeva EN; Boyarskih UA; Pospelova TI; Filipenko ML
Leuk Res; 2011 Apr; 35(4):508-15. PubMed ID: 21055808
[TBL] [Abstract][Full Text] [Related]
47. Genomic rearrangement of the c-myc proto-oncogene in non-AIDS-related lymphoma in Japan.
Nagai M; Ikeda K; Tasaka T; Irino S
Leukemia; 1991 Jun; 5(6):462-7. PubMed ID: 2056771
[TBL] [Abstract][Full Text] [Related]
48. [Association of XRCC1 genetic polymorphism with susceptibility to non-Hodgkin's lymphoma].
Li SX; Zhu HL; Guo B; Yang Y; Wang HY; Sun JF; Cao YB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):982-7. PubMed ID: 25130814
[TBL] [Abstract][Full Text] [Related]
49. Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma.
Purdue MP; Lan Q; Kricker A; Vajdic CM; Rothman N; Armstrong BK
Haematologica; 2007 Aug; 92(8):1145-6. PubMed ID: 17650449
[TBL] [Abstract][Full Text] [Related]
50. Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin's lymphoma.
Song W; Liu MG; Zhang JB; Zhang JJ; Sun MM; Yu QK
Eur Rev Med Pharmacol Sci; 2016; 20(6):1093-7. PubMed ID: 27049262
[TBL] [Abstract][Full Text] [Related]
51. Methylenetetrahydrofolate reductase gene polymorphisms (677C > T and 1298A > C) in Egyptian patients with non-Hodgkin lymphoma.
Nasr AS; Sami RM; Ibrahim NY
J Cancer Res Ther; 2012; 8(3):355-60. PubMed ID: 23174714
[TBL] [Abstract][Full Text] [Related]
52. L-myc gene polymorphism and risk of thyroid cancer.
Yaylim-Eraltan I; Bozkurt N; Ergen A; Zeybek U; Ozturk O; Arikan S; Erbil Y; Uslu I; Camlica H; Isbir T
Exp Oncol; 2008 Jun; 30(2):117-20. PubMed ID: 18566574
[TBL] [Abstract][Full Text] [Related]
53. Association of stromal cell-derived factor-1-3'A polymorphism to higher mobilization of hematopoietic stem cells CD34+ in Tunisian population.
Ben Nasr M; Reguaya Z; Berraies L; Maamar M; Ladeb S; Ben Othmen T; Mellouli F; Béjaoui M; Domenech J; Jenhani F
Transplant Proc; 2011 Mar; 43(2):635-8. PubMed ID: 21440782
[TBL] [Abstract][Full Text] [Related]
54. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma.
Lee JT; Innes DJ; Williams ME
J Clin Invest; 1989 Nov; 84(5):1454-9. PubMed ID: 2509518
[TBL] [Abstract][Full Text] [Related]
55. Role of genetic factors in development and progression of non-Hodgkin's lymphomas.
Soucek P
Cent Eur J Public Health; 2001 May; 9(2):74-8. PubMed ID: 11503278
[TBL] [Abstract][Full Text] [Related]
56. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
Chang H; Blondal JA; Benchimol S; Minden MD; Messner HA
Leuk Lymphoma; 1995 Sep; 19(1-2):165-71. PubMed ID: 8574164
[TBL] [Abstract][Full Text] [Related]
57. Novel restriction fragment length polymorphisms in the cellular oncogene SEA.
Koduru PR; Goh JC; Broome JD
Hematol Pathol; 1992; 6(2):71-8. PubMed ID: 1351480
[TBL] [Abstract][Full Text] [Related]
58. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma.
Fernberg P; Chang ET; Duvefelt K; Hjalgrim H; Eloranta S; Sørensen KM; Porwit A; Humphreys K; Melbye M; Ekström Smedby K
Cancer Causes Control; 2010 May; 21(5):759-69. PubMed ID: 20087644
[TBL] [Abstract][Full Text] [Related]
59. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification.
Caron H; van Sluis P; van Hoeve M; de Kraker J; Bras J; Slater R; Mannens M; Voûte PA; Westerveld A; Versteeg R
Nat Genet; 1993 Jun; 4(2):187-90. PubMed ID: 8102298
[TBL] [Abstract][Full Text] [Related]
60. Oncogene rearrangement in non-Hodgkin's lymphoma with a 14q+ chromosome of unknown origin.
Nakamine H; Masih AS; Chan WC; Sanger WG; Armitage JO; Weisenburger DD
Leuk Lymphoma; 1993 May; 10(1-2):79-88. PubMed ID: 8374527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
